
金标说明书(SARS-CoV-2 Ag Test)N 尺寸:297x210mm 材质:70g双胶纸 双面黑白印刷(对折) 01.05.14.121-220402



CMYK:0/0/0/10

Rapid SARS-CoV-2 Antigen Test



ITP16030-TC7 ITP16030-TC5 ITP16030-TC2 ITP16030-TC1

For Self-testing Use.

For in vitro diagnostic use only. Please read the instructions for use carefully prior to use and strictly follow the instructions. User should not take any decision of medical relevance without first consulting his or her medical practitioner.

INTENDED USE

The Rapid SARS-CoV-2 Antigen Test is a colloidal gold enhanced, rapid immunochromatographic assay for qualitative detection of SARS-CoV-2 antigens in the nasal specimen collected by swabs from individuals who are suspected of having COVID-19. The test is used as an aid in the diagnosis of SARS-CoV-2 infection. This test is for self-testing

The test is for self-test with self-collected anterior nasal swab samples. It is indicated for the use of individuals aged 18 years or older with symptoms of COVID-19 within the first seven (7) days of symptom onset.

Testing of individuals without symptoms should be limited to contacts of confirmed or probable cases or to other epidemiological reasons to suspect a COVID-19 infection and should be followed by additional confirmatory testing with a molecular test.

SUMMARY

COVID-19 is a SARS-CoV-2 (also known as 2019-nCoV) associated pneumonia. A few patients have developed severe pneumonia, pulmonary oedema, ARDS, or multiple organ failure and have died. The Rapid SARS-CoV-2 Antigen Test is based on immunochromatography for detection of SARS-CoV-2 antigen in the specimen collected by the swab. It is simple, visual qualitative and presents the result within 20 minutes.

TEST PRINCIPLE

Gold conjugated mouse anti-SARS-CoV-2 N-protein IgG and gold conjugated rabbit nonspecific IgG are pre-coated on the sample pad. SARS-CoV-2 antigen (N protein) can react with the gold conjugated mouse SARS-CoV-2 specific IgG and form an immune complex. The specimen will move forward along the test strip. If the specimen contains SARS-CoV-2 antigen (N protein) and the concentration is above the minimum detection limit, the complex will be captured by the mouse anti-SARS-CoV-2 N-protein IgG pre-coated at the test band region, and form a purplish red band. If the specimen does not contain SARS-CoV-2 antigen or the concentration is below the minimum detection limit, there will be no purplish red band shown at the test band region.

Regardless of whether the analyte exist in the specimen, the gold conjugated rabbit nonspecific IgG will be captured by the goat anti-rabbit IgG. A purplish red band will appear at the control band region.

Only when the control band appears, the correlated result is valid.

STORAGE CONDITIONS AND STABILITY

The Rapid SARS-CoV-2 Antigen Test shall be stored at 2-30°C. The shelf life of the kit is 24 months. Please kindly refer the accurate expired date as indicated on the outer package. Test cassette should be used within 1 hour upon opening the foil pouch.

WARNINGS AND PRECAUTIONS

The warnings and precautions are included, but not limited to the following:

Warnings

This product is for in vitro diagnosis of the infection of SARS-CoV-2 only; other diseases cannot be analyzed with any component of this kit. All specimens with positive results must be confirmed using an appropriate test such as RT-PCR or equivalent

Precautions

Do not use expired reagents or test cassettes.

• Do not use the kit if any of the components is damaged or missing. () • Do not reuse the cassette, swab or test tube. ()

- If bleeding occurs, it may affect the test results. If blood is seen on the nasal swab, stop collecting the specimen and dispose the used swab. Please repeat the test with new test kit after the bleeding has stopped.
- Do not touch or drink the liquid inside the buffer tube. Do not allow it to come into contact with your skin, your eyes or any external surface If the solution makes contact with your skin, immediately wash your skin with water
- If the solution gets into your eyes, immediately wash them with water.
- If you experience any symptoms after contact with the liquid, seek medical help immediately.
- If the liquid inside the buffer tube is spilled, clean it using gloves and absorbent tissue.
- Do not store the specimen in test tube; it is only used for specimen processing
- Do not use pooled specimens or specimens other than specified (i.e. urine, blood).
- Do not interchange reagents among kits of different batch number or even products.
- Do not perform the test under environment which leads to rapid evaporation(e.g.>40°C and <40% RH, close to a running fan or air conditioner).
- Clean and disinfect all the areas that may be contaminated by spills of specimens or reagents with appropriate disinfectant to control infectious risks. Children and adolescents under the age of 18 or people who cannot understand the instructions of use correctly should only take the test under the
- supervision of an adult or someone who can fully understands the instructions of use correctly.
- Refer to the local regulations in force regarding the disposal of the testing materials.
- If you experience pain when taking a sample, pull the swab out immediately, otherwise injury may result.
- In the event of a positive result, you are advised to immediately contact the local health department or a doctor for further diagnosis and treatment. It is essential that you comply with all local regulations on self-isolation.
- If the test result is negative, a COVID-19 infection cannot be ruled out. Continue to comply with all applicable rules regarding contact with others and protective measures. If you experience any of the typical COVID-19 symptoms such as fever, cough, body aches, tiredness, runny nose or diarrhea or have had direct contact with a person who tested positive, you should immediately consult a doctor for further diagnosis and treatment and contact the local one Adhere to the rules of conduct recommended by local health authorities.

Reagents and materials provided

Table1 Reagents and materials provided

| Component | 25 tests (ITP16030-TC25) | 7 tests (ITP16030-TC7) | 5 tests (ITP16030-TC5) | 2 tests (ITP16030-TC2) | 1 test (ITP16030-TC1) | |
|-----------------------|--------------------------|------------------------|------------------------|---------------------------|---------------------------|--|
| Buffer tube | 350μL×25 pieces | 350μL×7 pieces | 350μL×5 pieces | 350μL×2 pieces | 350µL×1 piece | |
| Cassette | 1×25 pieces | 1×7 pieces | 1×5 pieces | 1×2 pieces | 1×1 piece | |
| Disposable swab | 1×25 pieces | 1×7 pieces | 1×5 pieces | 1×2 pieces | 1×1 piece | |
| Instructions for use | 1×1 piece | 1×1 piece | 1×1 piece | 1×1 piece | 1×1 piece | |
| Tube holder | 1×1 piece | 1×1 piece | 1×1 piece | stand hold of the package | stand hold of the package | |
| Quick operation guide | 1×1 piece | 1×1 piece | 1×1 piece | 1×1 piece | 1×1 piece | |

Note: Information of the disposable swab

| Accessory | Manufacturer | Authorized Representative | CE mark | |
|------------------|--|---|---------------|--|
| Disposable Swabs | Jiangsu Changfeng Medical Industry Co.,Ltd. TouqiaoTown,Guangling District Yang zhou,225109 Jiangsu,P.R.China | Llins Service&Consulting GmbH Obere Seegasse 34/2,69124 Heidelberg,Germany | STERILE EO CE | |

MATERIALS REQUIRED BUT NOT PROVIDED

Timer, clock or stopwatch
I plastic waste bag

TEST PROCEDURE

Preparation

- 1. Wash your hands and make sure they are dry before starting the test.
- 2. Carefully read the instructions for use prior to use Rapid SARS-CoV-2 Antigen Test.
- 3. Check the expiry date on the foil pouch. Do not use the kit if expiry date has passed.
- 4. Allow all reagents and specimens to reach room temperature (10-30°C) before use
- 5.Please refer to illustrations in the Quick operation guide

Collection

- 1. Peel off the foil from the top of the buffer tube 2. Set the buffer tube on the stand hole of the package
- 3. Open the swab package at stick end, take out the swab

Do not touch the fabric tip of the swab.

4. Insert the swab into the nostril cavity, gently turn and push the swab into the nasal cavity until it is blocked at the turbinate (about 2.0cm-2.5cm from the nostril). Rotate the swab 5 times against the wall of the nasal cavity and remove the swab. Use the same swab to sample the other nostril in the same way to ensure that you get enough samples.

A nasal swab specimen can be self-collected by an individual aged 18 years and older. For young people under 18 years should be tested by an adult. If you experience pain when taking a sample, pull the swab out immediately, otherwise injury may result. If bleeding occurs, it may affect the test Æ results. If blood is seen on the nasal swab, stop collecting the specimen and repeat the test with new kit after the bleeding has stopped.

Specimen treatment

1. Insert the fabric tip of the swab into the solution in the buffer tube, and rotate it against the inner wall of the buffer tube about 10 times to dissolve the specimen in the solution as much as possible. 2. Squeeze the tip of the swab along the inner wall of the buffer tube to keep the liquid in the tube as much as possible, then remove and discard the swab. 3. Press the nozzle cap tightly onto the buffer tube to avoid any leaks.

Specimen addition

1. Unseal the foil punch and put the cassette on a clean, dry and level surface. 2. Add 5 drops (~100µL) of treated specimen into "S" well of the cassette

3. Wait at least 15 minutes (and 20 minutes at most) to interpret the result.

RESULT INTERPRETATION

Negative: Colored band only appears on control band area indicates a negative result.

A negative result gives the absence of SARS-CoV-2 antigens. A negative result from a self-test is not 100% reliable. A negative result does not rule out a recent infection with SARS CoV-2. If you think you have contact with the virus (with infected person) in the last days before the test is carried out, we recommend that you take a Laboratory Test at the hospitals. Keep following the corona rules; keep your distance, wear mouth mask, wash your hands often and keep watching for complaints. If you have complaints or have had contact with infected person, have yourself tested at the hospital as soon as possible.

Positive: Colored bands appear at both the test band area (even though very weak) and the control band area indicates a positive result Why a retest?

A self-test is less reliable than the professional test at the hospitals. Therefore, there is a chance that your positive result is a false alarm. If the retest at the hospital is negative then you may be released from isolation.

Invalid: Colored band appears at neither the control band area nor the test band area of the cassette.

The test is not valid, do a new test. Reread the procedure and repeat the test with a new cassette. The most likely reasons for the control line not appearing are inadequately sample volume or improper procedural techniques (improper specimen collection, temperature and humidity conditions for performing the test), or tests left open for more than one hour or even expired.

Do not eat or smoke while handling specimens. /!\ Do not open the pouch until ready to perform a test.

(1)

Use the test under low environment humidity within 1 hour

3



In the event of a positive result, you are advised to immediately contact the local health department or a doctor for further diagnosis and treatment. It is essential that you comply with all local regulations on self-isolation. If the test result is negative, a COVID-19 infection cannot be ruled out. Continue to comply with all applicable rules regarding contact with others and protective measures. Should you experience any of the typical COVID-19 symptoms such as fever, cough, body aches, tiredness, runny nose or diarrhea or have had direct contact with a person who tested positive, you should immediately consult a doctor for further diagnosis and treatment and contact the local one adhere to the rules of conduct recommended by local health authorities. If the test did not work and is considered Invalid. This may be the result of an incorrect test procedure and the test should be repeated. Please perform a new test with a new sample and a new test.

Performance Characteristics

Clinical Evaluation Report

Clinical performance of Rapid SARS-CoV-2 Antigen Test was determined by testing 110 positive and 470 negative specimens for SARS-CoV-2 antigen to have a sensitivity of 93.64% and specificity of 100.00%. Clinical specimens were confirmed to be positive or negative using an RT-PCR reference method

Results analysis:

| | | | Positive Negative Total | | | | |
|-------------------------------|---------|---------------|-------------------------|-------|--------|--|--|
| | | Positive | Negative | Total | Sensi | | |
| | Positve | 103 | 0 | 103 | Spec | | |
| Rapid SARS-CoV-2 Antigen Test | | st Negative 7 | 470 | 477 | Total | | |
| | Total | 110 | 470 | 580 | *CI: C | | |

sitivity (Positive coincidence rate) : 103/110=93.64% (95%CI: 87.33%-97.40%) ificity (Negative coincidence rate): 470/470=100.00% (95%CI: 99.22%-100.00%) coincidence rate: 573/580=98.79% (95%CI: 97.53%~99.51%) Confidence Interval

Limit of Detection (LoD)

The LoD for Rapid SARS-CoV-2 Antigen Test was 4.25 x10² TCID_{so}/mL. The LoD is established using limiting dilutions of heat-inactivated SARS-CoV-2 antigen.

Cross-Reactivity

Rapid SARS-CoV-2 Antigen Test does not cross with the following common respiratory pathogens.

PCR

| S.N. | Potential Cross-Reactant | Species | Concentration | S.N. | Potential Cross-Reactant | Species | Concentration |
|------|-----------------------------|------------|------------------------|------|--------------------------|------------------|---|
| 1 | Coronavirus 229E | VR -740 | 10 ⁶ pfu/mL | 15 | Legionella | 33152 | 10 ⁷ cfu/mL |
| 2 | Coronavirus NL63 | COV-NL63 | 10⁰pfu/mL | 16 | Streptococcus pneumoniae | CGMCC 1.8722 | 10 ⁷ cfu/mL |
| 3 | Coronavirus OC43 | VR -1558 | 10⁰pfu/mL | 17 | Enterovirus A | CV-A10 | 10ºpfu/mL |
| 4 | Coronavirus HKU1 | COV-HKU1 | 10 ⁶ pfu/mL | 18 | Enterovirus B | Echovirus 6 | 10 ⁶ pfu/mL |
| 5 | Seasonal H1N1 influenza | A-H1N1 | 10ºpfu/mL | 19 | Staphylococcus aureus | CGMCC 1.2910 | 10 ⁷ cfu/mL |
| 6 | H3N2 influenza virus | A-H3N2 | 10⁰pfu/mL | 20 | Human metapneumovirus | HMPV | 10 ⁶ pfu/mL |
| 7 | H7N9 avian influenza virus | A-H7N9 | 10⁰pfu/mL | 21 | H5N1 influenza virus | A-H5N1 | 2.44 X 10 ⁵ TCID ₅₀ /mL |
| 8 | Influenza B Yamagata | B-Yamagata | 10⁰pfu/mL | 22 | Influenza B V | B/Shand ong/7/97 | 6.97 X 104 TCID ₅₀ /mL |
| 9 | Mycoplasma pneumoniae | 39505 | 10 ⁷ cfu/mL | 23 | Adenovirus type 3 | QSE77A210 | 2.99 X 10 ⁵ TCID ₅₀ /mL |
| 10 | Chlamydia pneumoniae | VR-2282 | 10 ⁷ cfu/mL | 24 | Mumps virus | HQ416906-S79-A | 6.96 X 104 TCID ₅₀ /mL |
| 11 | Coronavirus MERS | MERS | 10 ⁸ pfu/mL | 25 | Measles virus | Shanghai-191 | 8.6 X 104 TCID ₅₀ /mL |
| 12 | Parainfluenza virus type 1 | HPIVs-1 | 10⁰pfu/mL | 26 | Coxsackie virus 16 | | 13.44 μg/mL |
| 13 | Mycobacterium tuberculosis | 25177 | 10 ⁷ cfu/mL | 27 | Enterovirus Type 71 | | 4.7 μg/mL |
| 14 | Respiratory syncytial virus | RSV-A2 | 10ºpfu/mL | | | | |

Interfering Substances

The following potentially interfering substances have no impact on Rapid SARS-CoV-2 Antigen Test . The final test concentrations of the interfering substances are documented in the table below.

| S.N. | Substance Name | Concentration | S.N. | Substance Name | Concentration | S.N. | Substance Name | Concentration |
|------|----------------|---------------|------|----------------|---------------|------|-------------------------|---------------|
| 1 | Hemoglobin | 2 g/L | 9 | Levofloxacin | 2 mg/mL | 17 | Triamcinolone acetonide | 100 mg/mL |
| 2 | Mucoprotein | 20 mg/mL | 10 | Azithromycin | 500 mg/mL | 18 | Budesonide | 2 mg/mL |
| 3 | Zanamivir | 50 mg/mL | 11 | Ceftriaxone | 1 g/mL | 19 | Mometasone | 1 mg/mL |
| 4 | Ribavirin | 2 g/mL | 12 | Tobramycin | 2 g/mL | 20 | Fluticasone | 10 mg/mL |
| 5 | Oseltamivir | 200 mg/mL | 13 | Oxymetazoline | 1 g/mL | 21 | Biotin | 1.2µg/mL |
| 6 | Peramivir | 1 g/mL | 14 | Beclazone | 0.5 mg/mL | 22 | NaCl | 18mg/mL |
| 7 | lopinavir | 1 g/mL | 15 | Dexamethasone | 20 mg/mL | 23 | Sodium citrate | 9mg/mL |
| 8 | Ritonavir | 250 mg/mL | 16 | Flunisolide | 5 mg/mL | | | |

Hook Effect

There is no Hook effect under concentration of 3.40 x10° TCID_{E0}/mL. The Hook effect was established using limiting dilutions of heat-inactivated SARS-CoV-2 antigen.

Repeatability and reproducibility

The internal study results showed that the product has a good repeatability and reproducibility by within-run, between-run and batch-to-batch studies using in-house control panel as acceptance criteria

Limitations

The kit is designed to detect SARS-CoV-2 antigen in nasals pecimen collected by the provided swab. Other types of specimens may not supply accurate results and the device will not notify this kind of misuse to the user

- The intensity of test band does not necessarily correlate to the titer of antigen in specimen.
- The presence of the control band only indicates the flow of the conjugate

· This product is intended to detect SARS-CoV-2 antigen from individuals, clinical diagnosis on SARS-CoV-2 infection should not be made only based on the results of the product. • A negative result should not exclude the possibility of infection caused by SARS-CoV-2. A negative result can also occur in the following circumstances:

- Recently acquired SARS-CoV-2 infection
- Low levels of antigen below the detection limit of the test.
- SARS-CoV-2 antigen in the patient failed to react with specific antibody utilized in the assay configuration, in exceptional cases this may lead to observation of negative results.
- Specimens are not properly stored.

Extremely high concentration of a particular analyte.

Recently discovered type or subtype of SARS-CoV-2.

For reasons above, care should be taken in interpreting negative results. Other clinical data(e.g., symptoms or risk factors) should be introduced in conjunction with the test results.

Specimen with positive results should be retested with other technological method such as PCR under the guidance of local regulations before the clinical diagnosis is made.

Positive test results do not rule out co-infections with other pathogens.

• The product is not validated on specimens from infants, children, or patients on anti-retroviral treatment.

FREQUENTLY ASKED QUESTIONS (FAO)

1. What is the Rapid SARS-CoV-2 Antigen Test used for?

Rapid antigen tests are commonly used in the diagnosis of respiratory illnesses. In this case, the rapid antigen detection test looks for proteins produced by the SARS-CoV-2 virus, which is the virus that causes the disease called COVID-19. Antigen tests are immunoassays that detect the presence of a specific viral antigen, which means they identify people who currently have a viral infection.

2. Where can I get Rapid SARS-CoV-2 Antigen Test?

Rapid SARS-CoV-2 Antigen Test are available either by prescription or over the counter in a pharmacy or retail store without a prescription. 3. How quickly are results for Rapid SARS-CoV-2 Antigen Test available?

Turnaround time for results is usually very quick. In this case, you can get the result within 15-20 minutes.

4. How does the test kit work?

The N protein of the SARS-CoV-2 virus reacts with the stripe-like coating of the test line and if present, results in a color change purplish red line appears. Therefore, if the sample does not contain any viral proteins or antigens, there will be no purplish red appearing on test (T) line

5. When should/can I test myself?

You can test yourself whether you have symptoms or not. Antigen rapid tests are most likely to perform well in patients with high viral loads which usually appear in the pre-symptomatic (1-3 days before symptom onset) and early symptomatic phases of their illness (within the first 5-7 days of illness). 6. What can affect my test result? What should I pay attention to?

Be sure to visibly collect sample material (nasal secretions). Perform the test immediately after taking the sample. Follow the instructions for use carefully. Apply the drops of extraction buffer only to the sample well (S). Too many or too few drops of extraction solution can lead to an invalid or incorrect test result. 7. What should I do, if there is no C (Control) line appearing?

Your test result is invalid. Repeat the test according to the instructions for use.

8. How to interpret the results?

Purplish red bands appearing at both test band area (even though very weak) and control band area indicates a positive result.

Purplish red band only appearing on control band area indicates a negative result.

If you are still unsure about the results, contact the nearest health facility according to the recommendations of your local authorities. 9. What should I do with the positive or negative results?

If your result is positive, you should contact the medical facility as recommended by your local authorities. Your test result may be double-checked and the

authority or facility will explain the appropriate next steps.

If your result is negative, this may mean that no virus is detected or the viral load is too low to be detected. If you experience symptoms (headache, fever, migraine, loss of sense of smell or taste, etc.), please consult your primary care physician in the nearest health care facility as recommended by your local authorities. If you are not sure, you can repeat the test.

10. How can l dispose of the testing materials?

Please refer to the local regulations in force regarding the disposal of the testing materials.


KEY TO SYMBOLS USED

| Â | CAUTION | Ť | KEEP DF | ۲Y | 2 | DO NOT REUSE | | | | | USE-BY DATE |
|------|----------------------------|---|------------------------------------|-----|----------------------|--------------------------------------|------------------------------------|--------------|---------------|-----|--|
| 鯊 | KEEP AWAY FROM SUNLIGHT | ī | CONSULT INS FOR | | ΣN | CONTAINS SUFFICIENT FOR (N) TESTS | | | | EEO | STERILIZED USING ETHYLENE OXIDE |
| 2'C- | LIMITATION | | IN VITRO DIAGNOST MEDICAL DE | ГІС | | C | O NOT USE PACKAGE IS DAMAGED | 5 | EC | REP | AUTHORISED REPRESENTATIVE IN THE EUROPEAN COMMUNITY |
| LOT | BATCH CODE | | TALOGUE NUMBER | CE | EUROPEAN CONFORMI | | | DATE MANU | OF FACTURE | | MANUFACTURER |

BIBLIOGRARHY

Susan R, Weiss, Julian L, Leibowitz, Coronavirus Pathogenesis, Advances in Virus Research, Band 81: 85-164 Shuo Su, Gary Wong, Weifeng Shi, et al. Epidemiology, Genetic recombination, and pathogenesis of coronaviruses. Trends in Microbiology, Juni 2016, Band 24, Nr. 6: 490-502

> REP EC



Tel: +86 592 6807188

Website: www.intecasi.com 332 Xinguang Road, Xinyang Industrial Area, Haicang, 361022, Xiamen, Fujian, P.R. China Email: intecproducts@asintec.com

